Doug Janzen

Biography

Over 20 years of experience in life sciences with leadership experience in corporate finance, business development, and operational management of life sciences companies. Doug is currently Co-Founder and Managing Director of Northview Ventures. Doug serves as Chairman and CEO of Aequus Pharmaceuticals (AQS-TSXV), a company that was founded within Northview. Prior to Northview Ventures, Doug was President and CEO of Cardiome Pharma (NASDAQ: CRME) Mr. Janzen held a series of positions including Chief Financial Officer (2003 - 2005), President and Chief Business Officer (2005 – 2009), and President and Chief Executive Officer (2009 – 2012). During this time he raised over $300 million from investors, completed over $1 billion in licensing deals, and lead a partnership with Merck to bring Cardiome’s lead product, Brinavess, through to clinical approval and marketing in Europe. Mr. Janzen currently serves on the Boards of Aequus Pharmaceuticals, Alabaster Technologies, Abcellera (Chairman), Ico Therapeutics, Perimeter Medical Imaging, Renaissance Biosciences and Synaptive Technologies. Prior to Cardiome Doug was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences and has completed over $1B in equity financing for Canadian biotech companies. Doug is Past Chair of LifeSciences BC, has served as a Director with Biotech Canada and is a past winner of Business in Vancouver’s “Top 40 Under 40 Award”.Biotechnology

Research Interest

Biotechnology